The ATTD of DM decreased then increased (linear, P = 0.001; quadratic, P = 0.003) as TIU/mg of complete feed increased in the ...

Obexelimab Phase 3 INDIGO trial topline results in Immunoglobulin G4-Related Disease (IgG4-RD) expected around year-end 2025 -- Reported highly ...

The drug, delivered by EMS as a single injection, improved infarct-related patency at cath lab arrival and 30-day clinical outcomes.

Then David, who leads the Factor XI clinical program at Regeneron, will present preclinical data as well as clinical data from the ROXI-VTE-I and II studies in venous thromboembolism prevention post ...

UBS Global Healthcare Conference 2025 November 10, 2025 2:00 PM ESTCompany ParticipantsAngela Wirick - Chief Financial ...

Doctors have always told patients with atrial fibrillation (AF) to limit caffeine, saying it could trigger irregular heartbeats, however, a new international trial shows that moderate coffee intake is ...

DWTX READ THE FULL DWTX RESEARCH REPORT Business Update 100 Patients Enrolled in Phase 2b Trial of Halneuron®; Interim ...

Shift verification effort from a single, time-consuming flat run to a more efficient, distributed, and scalable process.

Modern semiconductor chip design faces growing complexity due to numerous timing scenarios driven by varying operating ...

Circ-EGFR was identified as a novel predictive biomarker for cetuximab efficacy in KRAS wild-type metastatic colorectal ...

Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of small molecule antibiotics for difficult-to-treat bacterial ...

Proof-of-concept trials confirm robust anti-clotting effects for Regeneron’s two mechanistically-distinct antibodies against factor XI, in patients undergoing total knee replacement Trial results cons ...